Dr Reddy
-
Dr Reddy’s Laboratories completes first implementation phase of Werum’s standard MES
Dr Reddy’s is the first Indian company to improve its manufacturing processes by installing an electronic PAS-X Manufacturing Execution System (MES). Dr Reddy’s opted for Werum’s MES PAS-X to help enhance the quality and compliance and to optimize the efficiency and productivity of its pharmaceutical shop floor processes.
Dr Reddy | 17 January 2012
-
Dr Reddy's starts phase 2 study with CETP inhibitor in dyslipidemia patients
Dr Reddy's Laboratories announced the initiation of dosing with DRL-17822 in patients with diagnosis of type 2 dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.
Dr Reddy | 05 September 2011
-
FUJIFILM, Dr Reddy's establish exclusive joint venture on generic drugs in Japan
FUJIFILM Corporation President and CEO, Shigetaka Komori and Dr Reddy's Laboratories Ltd Vice-Chairman and CEO, G V Prasad signed a memorandum of understanding to enter into an exclusive partnership in the generic drugs business for the Japanese mark…
Dr Reddy | 29 July 2011
-
Oceana Therapeutics announces strategic alliance with Dr Reddy in India
Oceana Therapeutics announced that it has entered into a multi-year exclusive agreement with Indian pharmaceutical giant Dr Reddy’s Laboratories Ltd giving rights to the sale and distribution of Deflux in India. Further terms of the transaction wer…
Dr Reddy | 17 May 2011
-
Dr Reddy's Launches Transdermal Patch for Pain Management in India
Dr Reddy’s Laboratories has launched Finrid (Fentanyl Transdermal Patch) in India. Used in the management of severe to moderate pain, the patch provides the continuous systemic delivery of Fentanyl, an opioid analgesic for up to 72 hours. It is…
Dr Reddy | 25 September 2009
-
Dr Reddy’s Partners with GSK to Supply Emerging Markets
Dr Reddy’s Laboratories has announced a partnership with GlaxoSmithKline (GSK) to develop and market select products across emerging markets outside India. Under the terms of the agreement, the latter will gain access to the former’s portfolio…
Dr Reddy | 23 July 2009
-
Dr Reddy’s acquires BASF’s pharmaceutical contract manufacturing business
Dr Reddy’s Laboratories announced it has signed a definitive agreement to acquire BASF’s pharmaceutical contract manufacturing business and related facility in Shreveport, Louisiana, US. This transaction is subject to customary closing condit…
Dr Reddy | 09 May 2008
-
SkyePharma, Dr Reddy's Laboratories Collaborates In New Product
SkyePharma PLC said it has entered into an agreement with Dr Reddy's Laboratories to undertake a feasibility study. The costs of this study, of a product utilizing two of SkyePharma's proprietary drug delivery systems, will be paid for by Dr Redd…
Dr Reddy | 04 March 2008
-
Dr Reddy's Starts Operations In Philippines
Dr Reddy’s pharmaceutical company has expanded its presence in the ASEAN region with the opening of its 41st overseas office in Manila, Philippines in partnership with Britton Marketing Corporation, a sister company of Britton Distributions, Inc. …
Dr Reddy | 22 October 2007
-
Rheoscience and Dr Reddy’s commence the first Phase III trial of Balaglitazone
Rheoscience A/S and Dr Reddy’s Laboratories have announced that the first patient has been dosed in a Phase III study with Balaglitazone (DRF2593-307), which is an insulin sensitizer that acts as a partial PPAR (peroxisome proliferator-activated re…
Dr Reddy | 02 August 2007
